
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Recipient : UMass Dartmouth
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth
Details : The renewal and expansion of this collaboration recognizes the success of Associate Professor of Chemistry & Biochemistry Dr. David R. Manke and his associated team of researchers in the synthesis and crystallography of novel tryptamines.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Undisclosed
December 09, 2020
Lead Product(s) : Tryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Recipient : UMass Dartmouth
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Recipient : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
CaaMTech Collaborates With National Institutes of Health to Research Psychedelics
Details : The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 07, 2020
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
